India commoditised Novo's blockbuster obesity drug. Novo's not flinching
· 10 min · Episode 717
Episode India commoditised Novo's blockbuster obesity drug. Novo's not flinching
Semaglutide's patent just expired in India. The molecule behind Novo Nordisk's blockbuster obesity drugs, Ozempic and Wegovy, is now fair game for generic manufacturers. An 85 to 90% price drop is expected.
Eli Lilly's Mounjaro had already been outselling Wegovy.
For most companies, this would be the beginning of an exit. But Novo is doing the opposite. Why?
Tune in.
Daybreak is produced from the newsroom of The Ken, India’s first subscriber-only business news platform. Subscribe for more exclusive, deeply-reported, and analytical business stories.
Links in the notes 1
Shows are listed from Apple Podcasts' charts and directory, and Podcast Index where it is used. Every show and episode belongs to its publisher and plays from the publisher's own feed; this site hosts none of them. Explicit shows are for adult profiles only, and children’s profiles hear only children’s shows. More about this list.